908 Devices Inc.
- Open
- 8.72
- Day high
- 8.97
- Day low
- 8.56
- Prev close
- 8.70
- Volume
- 79K
- Mkt cap
- $337M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 2.5
- P/S
- 5.8
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$4.7M over the last 3 months (0 open-market buys, 30 sales)
- 🏛Institutions mixed (13F)
908 Devices Inc. (MASS) is a Healthcare company listed on NASDAQ. The stock is up 34% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 30 sales (SEC Form 4).
908 Devices Inc. (MASS) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
MASS earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 6, 2026 | $-0.15 | $-0.22 | -46.7% | $13M | +1.7% |
| Mar 3, 2026 | $-0.06 | $-0.05 | +16.7% | $17M | +29.4% |
| Mar 4, 2025 | $-0.35 | $-0.32 | +8.6% | $19M | +54.8% |
| Apr 30, 2024 | $-0.37 | $-0.33 | +10.8% | $10M | -26.8% |
| Mar 5, 2024 | $-0.27 | $-0.23 | +14.8% | $14M | +1.3% |
| Mar 7, 2023 | $-0.22 | $-0.31 | -40.9% | $12M | +1.9% |
| Nov 14, 2022 | $-0.22 | $-0.20 | +9.1% | $16M | +0.7% |
| Mar 7, 2022 | $-0.18 | $-0.12 | +33.3% | $16M | +4.8% |
| Nov 4, 2021 | $-0.15 | $-0.19 | -26.7% | $13M | +4.3% |
| Aug 4, 2021 | $-0.22 | $-0.27 | -22.7% | $8M | +15.8% |
| May 13, 2021 | $-0.22 | $-0.22 | +0.0% | $6M | +0.0% |
| Dec 18, 2020 | — | $0.11 | — | $11M | — |
MASS insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 30, 2026 | Knopp Kevin J.director, officer: President and CEO | Sell | 2,798 | $9.09 |
| Jun 25, 2026 | Knopp Kevin J.director, officer: President and CEO | Sell | 16,388 | $9.10 |
| Jun 25, 2026 | Knopp Kevin J.director, officer: President and CEO | Sell | 3,422 | $9.06 |
| Jun 25, 2026 | Leonhart Michele M.director | Option | 6,486 | — |
| Jun 25, 2026 | Knopp Kevin J.director, officer: President and CEO | Sell | 40,535 | $9.14 |
| Jun 25, 2026 | Brown Christopher D.director | Sell | 9,900 | $9.04 |
| Jun 24, 2026 | AWM Investment Company, Inc.10 percent owner | Sell | 3,050 | $9.00 |
| Jun 24, 2026 | AWM Investment Company, Inc.10 percent owner | Sell | 4,668 | $8.99 |
| Jun 12, 2026 | CRANDELL KEITHdirector | Grant | 6,209 | $8.22 |
| Jun 12, 2026 | Leonhart Michele M.director | Option | 14,083 | — |
| Jun 12, 2026 | HRUSOVSKY E KEVINdirector | Grant | 6,209 | $8.22 |
| Jun 12, 2026 | Hunt Anthonydirector | Grant | 6,209 | $8.22 |
| Jun 12, 2026 | CRANDELL KEITHdirector | Option | 14,083 | — |
| Jun 12, 2026 | Vann Brandi Cdirector | Grant | 13,656 | — |
| Jun 12, 2026 | Hunt Anthonydirector | Option | 14,083 | — |
Source: MASS SEC Form 4 filings, latest Jun 30, 2026. For informational purposes only — not investment advice.
See the full MASS insider & 13F page →908 Devices Inc. company profile
Overview
908 Devices Inc. (NASDAQ:MASS) is a commercial-stage technology company founded in 2012 and headquartered in Boston, Massachusetts. The company specializes in developing and manufacturing portable mass spectrometry and analytical devices for chemical detection and analysis. Since going public in December 2020, 908 Devices has focused on serving markets including life sciences research, bioprocessing, forensics, and industrial applications with its handheld and desktop analytical instruments.
Business
908 Devices operates in the analytical instrumentation industry, specifically focusing on mass spectrometry technology. Mass spectrometry is a scientific technique that identifies and quantifies molecules by measuring their mass-to-charge ratio, essentially allowing users to determine what chemicals are present in a sample and in what quantities. The company's core products fall into two main categories: Handheld Devices (approximately 75-80% of revenue): The flagship product is the MX908, a battery-powered handheld mass spectrometer designed for rapid field analysis of unknown gas, liquid, and solid materials. This device is primarily used by law enforcement, military, and security personnel for detecting drugs, explosives, and chemical threats. The company also offers FTIR (Fourier Transform Infrared) handheld devices through its RedWave Technology acquisition, which use infrared light to identify chemical compounds and are commonly used for material identification in forensics and industrial applications. Desktop/Process Analytical Devices (approximately 20-25% of revenue): These include the Rebel system, a desktop analyzer that provides real-time monitoring of bioprocesses by measuring the extracellular environment in bioreactors used for pharmaceutical manufacturing. The ZipChip solution is a plug-and-play separation platform that optimizes mass spectrometry sample analysis for research applications. The company also offers MAVEN, an online glucose and lactate monitoring system for bioprocessing. The company generates approximately 37% of its revenue from recurring sources, including consumables, service contracts, and software subscriptions that support the installed base of devices. This recurring revenue model provides some stability to the business as customers continue to purchase consumables and maintain their equipment over time.
Revenue model
908 Devices operates on a product sales and recurring revenue model. The company generates revenue through direct sales of analytical instruments, ranging from handheld devices priced typically between $50,000-$100,000 to desktop systems that can cost $200,000 or more. The primary customers include government agencies (law enforcement, military, homeland security), pharmaceutical and biotechnology companies, forensic laboratories, and research institutions. The business model has two main revenue streams: 1) Initial device sales which provide the bulk of revenue, and 2) Recurring revenue from consumables, service contracts, and software subscriptions that currently represents 37% of total revenue. This recurring component grows as the installed base expands, providing increasing revenue stability over time. Several factors influence the company's margins and profitability. Positive margin drivers include the high-value nature of the products which command premium pricing due to their specialized capabilities, the growing recurring revenue base that typically carries higher margins, and economies of scale as manufacturing volumes increase. The company has also undertaken cost optimization initiatives, including consolidating manufacturing operations and workforce reductions that are expected to save over $4 million annually. Margin pressures come from several sources: extended sales cycles particularly in the bioprocessing market where customers are conservative with capital expenditures, competitive pricing pressure as the market matures, and significant ongoing R&D investments required to maintain technological leadership. Additionally, the company faces macroeconomic headwinds that have led to delayed purchasing decisions, particularly affecting the higher-priced desktop instruments used in pharmaceutical manufacturing.
Competitive moat
908 Devices possesses a moderate technological moat based on its specialized expertise in miniaturizing mass spectrometry technology for portable applications. The company's primary competitive advantage lies in its ability to deliver laboratory-quality analytical capabilities in handheld, battery-powered devices - a significant technical achievement that requires deep expertise in mass spectrometry, miniaturization, and software integration. The strength of this moat is moderately defensible due to several factors: the technical complexity of miniaturizing mass spectrometry creates barriers to entry, the company has built relationships with key government customers who value proven reliability, and the installed base generates switching costs through training, consumables, and service relationships. Additionally, regulatory approvals and certifications required for forensic and security applications create some customer stickiness. However, the moat faces potential vulnerabilities. Larger analytical instrument companies like Thermo Fisher Scientific, Agilent, or Waters Corporation have significantly greater resources and could potentially develop competing portable technologies. Alternative analytical technologies such as advanced spectroscopy or emerging sensor technologies could potentially provide similar capabilities at lower costs. The company also faces competition from specialized players in specific market segments, and the relatively small size of 908 Devices limits its ability to invest in R&D compared to industry giants. The forensics and security markets provide some protection due to the critical nature of applications and the extensive validation required for new technologies, but the bioprocessing market is more competitive and price-sensitive, making the company's position there less secure.
Risks & safety
The company presents a strong balance sheet with adequate liquidity but ongoing profitability challenges. • Cash Position: $79.2 million in cash and short-term investments as of Q1 2025, providing substantial runway • Debt Level: Minimal debt with debt-to-equity ratio of only 2.4%, indicating low financial leverage risk • Burn Rate: Free cash flow burn of approximately $15 million quarterly, though company expects cash flow positivity in 2026 • Current Ratio: Strong liquidity with current ratio of 7.6x, indicating ability to meet short-term obligations • Valuation Metrics: Trading at 0.91x P/E ratio (due to one-time gain from asset sale), 0.99x price-to-book ratio • Solvency: Low solvency risk given strong balance sheet, though company is not yet consistently profitable • Other Considerations: Recent $70 million asset sale to Repligen strengthened cash position; company targeting positive adjusted EBITDA by Q4 2025
Recent development
Over the past few years, 908 Devices has undergone significant strategic transformation focused on portfolio optimization and market expansion. The most notable development was the divestiture of its desktop portfolio to Repligen for $70 million in early 2025, allowing the company to focus resources on its higher-growth handheld device business while strengthening its balance sheet. The company has expanded its product portfolio through the acquisition of RedWave Technology, which added FTIR handheld capabilities and strengthened its position in the forensics market. This acquisition has enabled cross-selling opportunities, with the integrated sales team achieving multi-system orders shortly after the acquisition. The company has also been developing next-generation products, including a new MX908 device planned for launch in 2026 and enhanced software capabilities across its product line. Operational efficiency initiatives have been a major focus, with the company consolidating manufacturing operations from Boston to lower-cost facilities in North Carolina and Connecticut, expected to generate $2.4 million in annual savings. Additionally, an 11% workforce reduction is projected to save $4.2 million annually while optimizing the sales organization for greater efficiency. The company has also been expanding its government and enterprise customer base, securing significant orders including a $2 million contract with the Texas Department of Public Safety and growing deployments with Homeland Security Investigations. International expansion has been another priority, with particular focus on the European Union's rescEU initiative and growing presence in multiple international markets.
MASS company profile · for informational purposes only — not investment advice.
Track MASS with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free